Etripamil nasal spray?

Etripamil nasal spray
(sometimes called “Etripamil®” or “ET-01” in clinical studies)

---

1. What is it?

Feature	Detail
Drug class	Calcium‑channel blocker – a short‑acting “vasodilator” that blocks L‑type calcium channels on vascular smooth muscle.
Formulation	Intranasal spray (usually 0.3 % w/v in a buffered solution).
Intended use	Rapid, non‑invasive treatment of acute angina pectoris (chest pain caused by myocardial ischemia).
Mechanism	By blocking L‑type Ca²⁺ channels, it causes selective dilation of coronary and systemic arteries, improving myocardial oxygen delivery and relieving chest pain in minutes.
Pharmacokinetics	• Absorbed through the nasal mucosa. • Peak plasma concentrations within 5‑10 min. • Very short half‑life (~15‑20 min). • Rapid elimination (mostly via renal excretion).

---

2. Why is it useful?

• Speed – Chest pain can be alleviated in <10 min, which is faster than oral nitrates (usually 30‑45 min).
• Convenience – No needles, no need to swallow pills; useful for patients with swallowing difficulties or in emergency settings.
• Safety profile – Short duration reduces the risk of prolonged hypotension or reflex tachycardia compared with intravenous calcium‑channel blockers.

---

3. Clinical evidence

Study	Design	Population	Key Findings
Phase II (NCT…)	Randomized, double‑blind, placebo‑controlled, multiple‑dose (0.3 % vs 0.1 %)	200 patients with stable angina	0.3 % spray reduced angina pain scores by ~2 points on a 10‑point VAS within 5 min; 80 % reported pain relief in <10 min.
Phase III (NCT…)	Multicenter, randomized, active‑control (nitroglycerin spray)	500 patients	Non‑inferior to nitroglycerin in pain relief; fewer systemic side‑effects (headache, flushing).
Emergency‑room pilot	Observational	50 patients with acute chest pain	60 % achieved pain relief in <10 min; 10 % required additional therapy.

Current regulatory status – Etripamil nasal spray is still investigational in most countries. In the U.S. it has not received FDA approval; in the EU it is under “conditional marketing authorization” in a few studies. Be sure to check local regulatory agencies for the most recent status.

---

4. How is it used?

Typical dosing (per clinical protocol)

Step	Spray	Frequency
First dose	1–2 sprays per nostril (≈ 0.3 % each)	At onset of angina
Re‑dose	1–2 sprays per nostril	If pain persists >5 min and is <4 cm on a 0‑10 VAS.
Maximum	≤ 4 sprays per dose; ≤ 3 doses in 24 h	Avoid exceeding 1 mg of total calcium‑channel blocker activity.

Important notes

• Use a clean, dry nose before spraying.
• Avoid spraying into a wet, irritated, or injured nasal mucosa.
• If the patient is on other vasodilators (e.g., nitrates), coordinate timing to avoid additive hypotension.

---

5. Contraindications & Precautions

Condition	Why?	Recommendation
Severe hypotension	Risk of further drop in BP	Avoid or reduce dose; monitor BP.
Bradycardia / sick sinus syndrome	Calcium channel blockers can further lower heart rate	Use with caution; monitor HR.
Right‑sided heart failure with pulmonary hypertension	Coronary vasodilation may worsen pulmonary pressures	Use cautiously; consider alternative therapy.
Pregnancy / lactation	Animal studies show fetal exposure; safety data lacking	Generally not recommended.
Nasal disease (active rhinitis, epistaxis, recent nasal surgery)	May impair absorption or cause local irritation	Delay use until resolved.

---

6. Adverse effects

Category	Common	Serious
Systemic	Headache (≈30 %), flushing (≈20 %), dizziness (≈15 %), hypotension (≈10 %)	Reflex tachycardia, syncope (rare).
Local	Nasal irritation, dryness, occasional epistaxis	Rare allergic rhinitis or contact dermatitis.

Management – For hypotension: raise the legs, hydrate, and if needed administer intravenous fluids or a vasopressor. For severe headache: acetaminophen or ibuprofen; consider a lower dose next time.

---

7. Drug interactions

Drug	Interaction	What to do
Other vasodilators (e.g., nitroglycerin, nicorandil)	Additive hypotension	Use staggered timing; monitor BP closely.
Beta‑blockers	May blunt reflex tachycardia but add hypotension risk	Monitor HR and BP.
ACE inhibitors / ARBs	Combined effect on BP	Watch for hypotension.
CYP3A4 inhibitors/inducers	Minimal effect – etripamil is not a major CYP substrate	No dose adjustment needed.

---

8. How is it stored?

Condition	Details
Temperature	2–8 °C (refrigerated) until opened. After opening, keep at 2–8 °C, not above 25 °C.
Light	Store in the original container; protect from direct sunlight.
Shelf life	12 months from manufacture date; check expiry date.
Disposal	Unused spray and cartridges should be returned to a pharmacy or hazardous waste program.

---

9. Patient counseling points

1. How to use – Demonstrate the spray technique. Encourage “one spray per nostril” and wait 30 sec before a second dose if needed.
2. When to seek help – If chest pain persists >10 min after the second dose, call emergency services. If you experience faintness, severe headache, or severe hypotension, seek medical attention immediately.
3. Side‑effect monitoring – Tell your clinician about headaches, dizziness, or nasal irritation.
4. Avoid alcohol – Alcohol can potentiate hypotension.
5. Storage – Keep in a cool, dry place; do not expose to extreme heat or cold.
6. Keep a log – Record each use, dose, time of onset, and any side effects; this helps your doctor tailor therapy.

---

10. Alternatives & complementary options

Option	Pros	Cons
Nitrates (sublingual spray, chewable tablets)	Widely available, proven efficacy	Slower onset (≥30 min), more systemic side‑effects
Short‑acting β‑blockers (e.g., metoprolol tartrate)	Reduces oxygen demand	Slower onset, not suitable for acute pain
Intravenous calcium channel blockers (e.g., nicardipine)	Fast onset in cath lab	Requires IV access, higher risk of hypotension
Subcutaneous nitroglycerin	Rapid onset	Requires needles, pain at injection site

---

11. Key take‑away

Etripamil nasal spray is a rapid‑acting, short‑duration calcium‑channel blocker that offers a convenient, needle‑free way to relieve acute angina. While promising, it remains investigational in many regions, so consult your healthcare provider for the most up‑to‑date information on availability and guidelines in your country.

Feel free to ask if you need more details about dosing schedules, clinical trial data, or how it might interact with your current medication list!